Update: Many Malaria Meds Still Fake, and Now the Real Ones Are Iffy Too
Over the summer we we reported the curious story behind a National Institutes of Health study, which had found a third of malaria medications taken around the world are fake. Most commentary on the research intimated that unscrupulous, large, likely Chinese pharmaceutical companies were to blame. It turned out the dummy pills were actually produced by small criminal syndicates, shoestring counterfeit operations run in garages and back rooms, pushing fake meds in convincing packaging to customers in their own communities. Fortunately, none of this would matter soon, we thought—because a promising vaccine against malaria was on the way. In a generation malaria would be, if not gone, certainly on its heels.
This week, the final trial on that promising vaccine will appear in the New England Journal of Medicine—and the surprising results are not encouraging. After an earlier trial showed that more than sixty percent of older children vaccinated would become resistant to the disease, follow-up trials on infants have fallen disappointingly short. In the latest trial, only thirty percent of children showed resistance, and that appears likely to wane dramatically after the first year.